Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takaya Murashima

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Journal of Medical Case Reports|December 22, 2023
Hepatic and lung methotrexate-associated polymorphic lymphoproliferative disorders arising during postoperative follow-up of renal cell carcinoma: a case reportYoshi Miyamoto, Chihiro Kawasoe, Kaoru Ito, et al.
World Journal of Urology|September 26, 2024
The efficacy of second-line tyrosine kinase inhibitor for patients with metastatic non-clear cell renal cell carcinoma following first-line immune-oncology combination therapyKazutoshi Fujita, Yuto Matsushita, Shingo Toyoda, et al.
Clinical Genitourinary Cancer|May 7, 2024
Comparison of Cabozantinib and Axitinib as Second-line Therapy After Nivolumab Plus Ipilimumab in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Comparative Analysis of Retrospective Real-world DataRyotaro Tomida, Masayuki Takahashi, Yuto Matsushita, et al.
Clinical Genitourinary Cancer|March 21, 2025
Effectiveness and Safety of Second-line Tyrosine Kinase Inhibitors After Discontinuation of First-line Immune-oncology Combination Therapy Because of Adverse Events in the Patients With Metastatic Renal Cell CarcinomaMasayuki Takahashi, Yuto Matsushita, Takahiro Kojima, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Journal of Medical Case Reports|December 22, 2023
Hepatic and lung methotrexate-associated polymorphic lymphoproliferative disorders arising during postoperative follow-up of renal cell carcinoma: a case reportYoshi Miyamoto, Chihiro Kawasoe, Kaoru Ito, et al.
World Journal of Urology|September 26, 2024
The efficacy of second-line tyrosine kinase inhibitor for patients with metastatic non-clear cell renal cell carcinoma following first-line immune-oncology combination therapyKazutoshi Fujita, Yuto Matsushita, Shingo Toyoda, et al.
Clinical Genitourinary Cancer|May 7, 2024
Comparison of Cabozantinib and Axitinib as Second-line Therapy After Nivolumab Plus Ipilimumab in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Comparative Analysis of Retrospective Real-world DataRyotaro Tomida, Masayuki Takahashi, Yuto Matsushita, et al.
Clinical Genitourinary Cancer|March 21, 2025
Effectiveness and Safety of Second-line Tyrosine Kinase Inhibitors After Discontinuation of First-line Immune-oncology Combination Therapy Because of Adverse Events in the Patients With Metastatic Renal Cell CarcinomaMasayuki Takahashi, Yuto Matsushita, Takahiro Kojima, et al.
Pageof 2